300 related articles for article (PubMed ID: 25154814)
21. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
[TBL] [Abstract][Full Text] [Related]
22. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
23. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
24. [Relationship between the Akt-regulated direct p53 mitochondrial translocation and the resistance to cisplatin of ovarian cancer cells].
Zhou Y; Wang SY; Yang XK; Wang HM
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):97-100. PubMed ID: 21575475
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo.
Zhang LL; Zhang J; Shen L; Xu XM; Yu HG
Mol Med Rep; 2013 May; 7(5):1387-90. PubMed ID: 23546174
[TBL] [Abstract][Full Text] [Related]
26. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax.
Kim CW; Lu JN; Go SI; Jung JH; Yi SM; Jeong JH; Hah YS; Han MS; Park JW; Lee WS; Min YJ
Int J Oncol; 2013 Nov; 43(5):1495-502. PubMed ID: 23970333
[TBL] [Abstract][Full Text] [Related]
27. Cell fate regulation by gelsolin in human gynecologic cancers.
Abedini MR; Wang PW; Huang YF; Cao M; Chou CY; Shieh DB; Tsang BK
Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14442-7. PubMed ID: 25246592
[TBL] [Abstract][Full Text] [Related]
28. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
29. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
30. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Wu YH; Huang YF; Chen CC; Chou CY
Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
[TBL] [Abstract][Full Text] [Related]
31. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.
Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
33. p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer.
Han CY; Patten DA; Lee SG; Parks RJ; Chan DW; Harper ME; Tsang BK
Mol Carcinog; 2019 Nov; 58(11):2161-2174. PubMed ID: 31486135
[TBL] [Abstract][Full Text] [Related]
34. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.
Ali AY; Farrand L; Kim JY; Byun S; Suh JY; Lee HJ; Tsang BK
Ann N Y Acad Sci; 2012 Oct; 1271(1):58-67. PubMed ID: 23050965
[TBL] [Abstract][Full Text] [Related]
35. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells.
Girouard J; Lafleur MJ; Parent S; Leblanc V; Asselin E
Gynecol Oncol; 2013 Feb; 128(2):335-43. PubMed ID: 23174537
[TBL] [Abstract][Full Text] [Related]
36. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
[TBL] [Abstract][Full Text] [Related]
37. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract][Full Text] [Related]
38. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
39. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
